Advertisement

Medical Oncology

, Volume 29, Issue 4, pp 2923–2931 | Cite as

Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells

  • Jia-xi Song
  • Wang-li Cao
  • Fang-qiu LiEmail author
  • Li-ning Shi
  • Xuan Jia
Original Paper

Abstract

Sperm protein 17 (Sp17) is a cancer testis antigen that has been shown to be overexpressed in a variety of gynecologic malignancies, in particular ovarian cancer. Emerging evidences indicate that Sp17 is involved in tumorigenesis and in the migration of malignant cells. It has been proposed as a useful target for tumor-vaccine strategies and a novel marker to define tumor subsets and predict drug response. However, the antitumor activity of anti-Sp17 monoclonal antibody (anti-Sp17 mAb) has not been investigated. In this study, the in vitro cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities of anti-Sp17 mAb were evaluated using Sp17-positive ovarian cancer cells as targets, Sp17-negative ovarian cancer cells as the control, and healthy human peripheral blood monocytes and healthy human serum as effectors. Our preliminary results indicate that the direct cytotoxicity of anti-Sp17 mAb against the investigated ovarian cancer cells was very weak. However, the cytotoxicity of anti-Sp17 mAb, mediated by peripheral blood mononuclear cells (PBMCs), as ADCC, or by human serum, as CDC, was relatively strong in the Sp17-positive ovarian cancer cells. This finding suggested that anti-Sp17 mAb could be a useful tool against ovarian cancer and may provide insight into the development of low side-effect targeting therapy for this malignant disease.

Keywords

Anti-Sp17 monoclonal antibody Antibody-dependent cell-mediated cytotoxicity Complement-dependent cytotoxicity Ovarian cancer 

Abbreviations

Sp17

Sperm protein 17

Anti-Sp17 mAb

Anti-Sp17 monoclonal antibody

ADCC

Antibody-dependent cell-mediated cytotoxicity activity

CDC

Complement-dependent cytotoxicity

CTA

Cancer testis antigen

CTL

Cytotoxic T lymphocytes

PBMCs

Peripheral blood monocytes

mCRPs

Membrane complement regulatory proteins

MAC

Membrane attack complex

Notes

Acknowledgments

The authors appreciate Liu Qi, PhD for the gift of SKOV3 and COC2 human ovary carcinoma cell lines. Funding support: This work was supported by a grant from National Nature Science Foundation of China (No. 81101978).

Conflict of interests

The authors declare that they have no conflict of interests.

References

  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: Cancer J Clincians. 2010;60(5):277–300.CrossRefGoogle Scholar
  2. 2.
    Kristedja TS, Morgan RJ, Cristea M. Targeted agents in ovarian cancer. Women’s Health (London, England). 2010;6(5):679–94.Google Scholar
  3. 3.
    Polakis P. Arming antibodies for cancer therapy. Curr Opin Pharmacol. 2005;5(4):382–7.PubMedCrossRefGoogle Scholar
  4. 4.
    O’Rand MG, Widgren EE, Fisher SJ. Characterization of the rabbit sperm membrane autoantigen, RSA, as a lectin-like zona binding protein. Dev Biol. 1988;129(1):231–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Kong M, Richardson RT, Widgren EE, O’Rand MG. Sequence and localization of the mouse sperm autoantigenic protein, Sp17. Biol Reprod. 1995;53(3):579–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Lea IA, Kurth B, O’Rand MG. Immune response to immunization with sperm antigens in the macaque oviduct. Biol Reprod. 1998;58(3):794–800.PubMedCrossRefGoogle Scholar
  7. 7.
    Lea IA, Richardson RT, Widgren EE, O’Rand MG. Cloning and sequencing of cDNAs encoding the human sperm protein, Sp17. Biochim Biophys Acta. 1996;1307(3):263–6.PubMedCrossRefGoogle Scholar
  8. 8.
    McLeskey SB, Dowds C, Carballada R, White RR, Saling PM. Molecules involved in mammalian sperm-egg interaction. Int Rev Cytol. 1998;177:57–113.PubMedCrossRefGoogle Scholar
  9. 9.
    Lacy HM, Sanderson RD. Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell–cell adhesion. Blood. 2001;98(7):2160–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Lim SH, Wang Z, Chiriva-Internati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood. 2001;97(5):1508–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Grizzi F, Gaetani P, Franceschini B, Di Ieva A, Colombo P, Ceva-Grimaldi G, et al. Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer. 2006;6:23.PubMedCrossRefGoogle Scholar
  12. 12.
    Straughn JM Jr, Shaw DR, Guerrero A, Bhoola SM, Racelis A, Wang Z, et al. Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer. 2004;108(6):805–11.PubMedCrossRefGoogle Scholar
  13. 13.
    Li FQ, Han YL, Liu Q, Wu B, Huang WB, Zeng SY. Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells. BMC Cancer. 2009;9:323.PubMedCrossRefGoogle Scholar
  14. 14.
    Li FQ, Liu Q, Han YL, Wu B, Yin HL. Sperm protein 17 is highly expressed in endometrial and cervical cancers. BMC Cancer. 2010;10:429.PubMedCrossRefGoogle Scholar
  15. 15.
    Liu Q, Li FQ, Han YL, Wang LK, Hou YY. Aberrant expression of sperm protein 17 enhances migration of ovarian cancer cell line HO-8910. Nat J Androl. 2008;14(11):982–6.Google Scholar
  16. 16.
    Chiriva-Internati M, Weidanz JA, Yu Y, Frezza EE, Jenkins MR, Kennedy RC, et al. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J Immunother. 2008;31(8):693–703.PubMedCrossRefGoogle Scholar
  17. 17.
    Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, et al. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PloS one. 2010;5(5):e10471.PubMedCrossRefGoogle Scholar
  18. 18.
    Li FQ, Zhang SX, An LX, Gu YQ. In vivo Molecular targeting effects of anti-Sp17- ICG-Der-02 on hepatocellular carcinoma evaluated by an optical imaging system. J Exp Clin Cancer Res. 2011;30:25.PubMedCrossRefGoogle Scholar
  19. 19.
    Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol. 2007;19(2):239–45.PubMedCrossRefGoogle Scholar
  20. 20.
    Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Design Dev Ther. 2009;3:7–16.Google Scholar
  21. 21.
    Li FQ, Yang AL, Miao JW, Zhang CH, Wu B, Zhang XH. Preparation and characterization of the monoclonal antibody against human sperm protein 17. Chin J Cellular Molecul Immunol. 2006;22(5):638–40.Google Scholar
  22. 22.
    Lin Y, Peng S, Yu H, Teng H, Cui M. RNAi-mediated downregulation of NOB1 suppresses the growth and colony-formation ability of human ovarian cancer cells. Medical Oncol (Northwood, London, England). 2011: [Epub ahead of print].Google Scholar
  23. 23.
    Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147–57.PubMedCrossRefGoogle Scholar
  24. 24.
    Richardson RT, Yamasaki N, O’Rand MG. Sequence of a rabbit sperm zona pellucida binding protein and localization during the acrosome reaction. Dev Biol. 1994;165(2):688–701.PubMedCrossRefGoogle Scholar
  25. 25.
    Grizzi F, Chiriva-Internati M, Franceschini B, Hermonat PL, Soda G, Lim SH, et al. Immunolocalization of sperm protein 17 in human testis and ejaculated spermatozoa. J Histochem Cytochem. 2003;51(9):1245–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Wen Y, Richardson RT, Widgren EE, O’Rand MG. Characterization of Sp17: a ubiquitous three domain protein that binds heparin. Biochem J. 2001;357(Pt 1):25–31.PubMedCrossRefGoogle Scholar
  27. 27.
    Grizzi F, Chiriva-Internati M, Franceschini B, Bumm K, Colombo P, Ciccarelli M, et al. Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem. 2004;52(4):549–54.PubMedCrossRefGoogle Scholar
  28. 28.
    Chiriva-Internati M. Sperm protein 17: clinical relevance of a cancer/testis antigen, from contraception to cancer immunotherapy, and beyond. Int Rev Immunol. 2011;30(2–3):138–49.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhang Y, Wang Z, Robinson WR, Lim SH. Combined real time PCR and immunohistochemical evaluation of sperm protein 17 as a cancer-testis antigen. Eur J Haematol. 2004;73(4):280–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Pisani F, Maini CL, Sciuto R, Dessanti L, D’Andrea M, Assisi D, et al. FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases. J Exp Clin Cancer Res. 2011;30:16.PubMedCrossRefGoogle Scholar
  31. 31.
    Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164(8):4178–84.PubMedGoogle Scholar
  32. 32.
    Crowe JS, Hall VS, Smith MA, Cooper HJ, Tite JP. Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material. Clin Exp Immunol. 1992;87(1):105–10.PubMedCrossRefGoogle Scholar
  33. 33.
    Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–58.PubMedCrossRefGoogle Scholar
  34. 34.
    Lencer WI, Blumberg RS. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol. 2005;15(1):5–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA. 2006;103(11):4005–10.PubMedCrossRefGoogle Scholar
  36. 36.
    Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635–42.PubMedCrossRefGoogle Scholar
  38. 38.
    Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S, et al. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targ. 2011;10(8):922–31.CrossRefGoogle Scholar
  39. 39.
    Hourcade D, Liszewski MK, Krych-Goldberg M, Atkinson JP. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. Immunopharmacology. 2000;49(1–2):103–16.PubMedCrossRefGoogle Scholar
  40. 40.
    Davies A, Lachmann PJ. Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res. 1993;12(3):258–75.PubMedCrossRefGoogle Scholar
  41. 41.
    Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol. 2003;131(2):254–63.PubMedCrossRefGoogle Scholar
  42. 42.
    Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res. 2005;11(6):2327–36.PubMedCrossRefGoogle Scholar
  43. 43.
    Gelderman KA, Kuppen PJ, Okada N, Fleuren GJ, Gorter A. Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model. Cancer Res. 2004;64(12):4366–72.PubMedCrossRefGoogle Scholar
  44. 44.
    Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, et al. Mechanism by which orally administered beta-1, 3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol. 2004;173(2):797–806.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jia-xi Song
    • 1
  • Wang-li Cao
    • 1
  • Fang-qiu Li
    • 1
    Email author
  • Li-ning Shi
    • 1
  • Xuan Jia
    • 1
  1. 1.Laboratory of Molecular Biology, Institute of Medical Laboratory Sciences, Jinling Hospital, School of MedicineNanjing UniversityNanjingPeople’s Republic of China

Personalised recommendations